Climb Bio (CLYM) Director Thomas Basil Sells 100,000 Shares

What Happened

• Thomas Stephen Basil, a director of Climb Bio, sold 100,000 shares of Climb Bio common stock in an open-market disposition on September 15, 2026. The weighted-average sale price was $13.67 per share, generating aggregate proceeds of approximately $1,366,820. The sale was reported under transaction code "S" (sale).

Key Details

• Transaction date: 2026-09-15 (reported 2026-09-17; filing appears timely)
• Price: Weighted average $13.67; individual trade prices ranged from $13.38 to $14.34 (per filing)
• Shares sold: 100,000; Total proceeds ≈ $1,366,820
• Footnote F1: Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026 (pre-arranged plan)
• Footnote F2: Price is a weighted average; reporting person will provide breakdown of shares sold at each price on request
• Footnote F3: The filing’s reported beneficial ownership includes 413,312 shares distributed by Sera Medicines, LLC to certain limited partners, including the reporting person
• Filing timeliness: Reported two days after the transaction date, which is within the usual Form 4 reporting window (not indicated as late)

Context

• The sale was made under a 10b5-1 plan, which generally indicates the trades were pre-scheduled and not necessarily a contemporaneous view of the company’s prospects. This is a routine insider sale rather than a purchase signal; retail investors should weigh this information alongside other insider activity and company fundamentals.